RENALYTIX PLC LS-0025 Market Cap ($39.89 Million)
Market Cap & Net Worth: RENALYTIX PLC LS-0025 (2O9)
RENALYTIX PLC LS-0025 market cap. RENALYTIX PLC LS-0025 (F:2O9) has a market capitalization of $39.89 Million (€34.12 Million) as of October 30, 2026. Listed on the F stock exchange, this Germany-based company holds position #22586 globally and #1988 in its home market, demonstrating a 1.64% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying RENALYTIX PLC LS-0025's stock price €0.06 by its total outstanding shares 670459333 (670.46 Million).
RENALYTIX PLC LS-0025 Market Cap History (2020–2026)
RENALYTIX PLC LS-0025 market cap history from 2020 to 2026. Data shows change from $4.12 Billion to $48.60 Million (-51.89% CAGR). Check current stock price of RENALYTIX PLC LS-0025 for real-time trading data and today's change.
RENALYTIX PLC LS-0025 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how RENALYTIX PLC LS-0025's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see how efficiently does RENALYTIX PLC LS-0025 generate cash for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
16.33x
RENALYTIX PLC LS-0025's market cap is 16.33 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $548.69 Million | $2.97 Million | -$45.28 Million | 184.74x | N/A |
| 2023 | $146.58 Million | $3.40 Million | -$45.61 Million | 43.07x | N/A |
| 2024 | $88.57 Million | $2.30 Million | -$45.50 Million | 38.51x | N/A |
| 2025 | $48.99 Million | $3.00 Million | -$20.40 Million | 16.33x | N/A |
Competitor Companies of 2O9 by Market Capitalization
Companies near RENALYTIX PLC LS-0025 in the global market cap rankings as of October 30, 2026. See RENALYTIX PLC LS-0025 (2O9) net asset quality to understand what proportion of total assets are financed by equity.
Key companies related to RENALYTIX PLC LS-0025 by market ranking:
- Veeva Systems Inc Class A (NYSE:VEEV): Ranked #723 globally with a market cap of $37.44 Billion USD.
- Pro Medicus Ltd (AU:PME): Ranked #1627 globally with a market cap of $14.57 Billion USD ( AU$20.59 Billion AUD).
- Tempus AI, Inc. Class A Common Stock (NASDAQ:TEM): Ranked #2018 globally with a market cap of $11.06 Billion USD.
- BrightSpring Health Services, Inc. Common Stock (NASDAQ:BTSG): Ranked #2077 globally with a market cap of $10.63 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #723 | Veeva Systems Inc Class A | NYSE:VEEV | $37.44 Billion | $310.34 |
| #1627 | Pro Medicus Ltd | AU:PME | $14.57 Billion | AU$197.09 |
| #2018 | Tempus AI, Inc. Class A Common Stock | NASDAQ:TEM | $11.06 Billion | $77.84 |
| #2077 | BrightSpring Health Services, Inc. Common Stock | NASDAQ:BTSG | $10.63 Billion | $60.22 |
Market Capitalization of RENALYTIX PLC LS-0025 (2020–2026)
Market capitalization of RENALYTIX PLC LS-0025 from 2020 to today. Between 2020 and today, RENALYTIX PLC LS-0025's market cap moved from $4.12 Billion to $ 48.60 Million, with a yearly change of -51.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €48.60 Million | -0.80% |
| 2025 | €48.99 Million | -44.69% |
| 2024 | €88.57 Million | -39.57% |
| 2023 | €146.58 Million | -73.29% |
| 2022 | €548.69 Million | -90.07% |
| 2021 | €5.53 Billion | +34.29% |
| 2020 | €4.12 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of RENALYTIX PLC LS-0025 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $39.89 Million USD |
| MoneyControl | $39.89 Million USD |
| MarketWatch | $39.89 Million USD |
| marketcap.company | $39.89 Million USD |
| Reuters | $39.89 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About RENALYTIX PLC LS-0025
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from … Read more